Clearside Biomedical (CLSDQ) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for May 30, 2025, with four key proposals for shareholder vote, including director elections, executive compensation, auditor ratification, and an amendment to increase authorized common stock shares from 200M to 400M.

• Record date for voting is April 1, 2025; 77,279,286 shares outstanding and entitled to vote.

• Proxy materials are primarily provided online, with options for paper copies upon request.

Voting matters and shareholder proposals

• Shareholders will vote on electing three directors, approving executive compensation (say-on-pay), ratifying Ernst & Young LLP as auditor, and amending the certificate of incorporation to increase authorized shares.

• Board recommends voting FOR all proposals.

• Shareholder proposals for the 2026 meeting must be submitted by December 19, 2025, for inclusion in proxy materials.

Board of directors and corporate governance

• Board consists of nine members, with a majority deemed independent under Nasdaq standards.

• Board leadership is separated, with an independent chairperson.

• Board met four times in 2024; all members attended at least 75% of meetings.

• Three standing committees: Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.

• Board values diversity in skills, experience, and backgrounds, though no formal diversity policy exists.